Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

240 Views

Poster Session: HIV: Treatment

1252 - A Real-World Observational Study on HIV-Infected Patients who Switched from Nevirapine + 2 Nucleoside Reverse Transcriptase Inhibitors to Dolutegravir/Lamivudine in British Columbia, Canada

Friday, October 21, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Presenting Author(s)

Jd

Joss de Wet, MBChB CCFP FCFP

Clinical Assistant Professor
University of British Columbia
Vancouver, British Columbia, Canada

Co-Author(s)

JB

Joann K. Ban, PharmD, MSc

GlaxoSmithKline Canada Inc.
Mississauga, Ontario, Canada
GV

Gustavo Verdier, BSc, BPharm, MBA

ViiV Healthcare, Montréal, QC, Canada
Pointe-Claire, Quebec, Canada
JL

Juejing Ling, MSc

IQVIA Solutions Canada Inc.
Toronto, Ontario, Canada
ME

Maria Eberg, MSc

Senior Consultant
IQVIA
Kirkland, Quebec, Canada
AB

Andrean Bunko, MPH

Consultant
IQVIA Solutions Canada Inc.
Mississauga, Ontario, Canada
MM

Michael McKimm, BSc

ViiV Healthcare
North Vancouver, British Columbia, Canada